Drug KP104 for IgA or C3 kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests KP104 in people with IgA nephropathy (IgAN) or C3 glomerulopathy (C3G) to see if it improves kidney disease and is safe. It also tracks how the body handles the drug and how it affects disease markers in urine and blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than the study’s minimum age (not listed here) and weigh more than 35 kg
- Have a BMI under 35
- Have urine protein levels high enough: UPCR above 1.0 from a 24-hour urine test
- Have a kidney biopsy-confirmed diagnosis of IgAN or C3G within the last 3 years
- Be on a stable treatment plan for at least 6–12 weeks before screening (ACE/ARB and/or SGLT2, if applicable)
- Agree to birth control rules if you can become pregnant, and have a negative pregnancy test if required
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests a new medicine, RG002C0106, to see how it is processed in people with normal or mildly to moderately reduced kidney function. It helps researchers understand how kidney function affects the drug, which is important for future dosing recommendations.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial tests a new treatment called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug can safely reduce protein in the urine and help protect kidney function.
Hear when a new Glomerulonephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.